Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.600
0.00 (0.00%)
Oct 28, 2025, 12:14 PM EDT - Market open
Mainz Biomed Revenue
Mainz Biomed had revenue of $286.72K in the half year ending June 30, 2025, a decrease of -42.55%. This brings the company's revenue in the last twelve months to $659.94K, down -28.05% year-over-year. In the year 2024, Mainz Biomed had annual revenue of $893.99K, down -0.17%.
Revenue (ttm)
$659.94K
Revenue Growth
-28.05%
P/S Ratio
5.48
Revenue / Employee
$25,382
Employees
26
Market Cap
8.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 893.99K | -1.49K | -0.17% |
| Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
| Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
| Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
| Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MYNZ News
- 20 days ago - Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire
- 2 months ago - Mainz Biomed Announces Registration of ColoAlert in the United Kingdom - GlobeNewsWire
- 2 months ago - Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® - GlobeNewsWire
- 3 months ago - Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewsWire
- 3 months ago - Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies - GlobeNewsWire
- 3 months ago - Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition - GlobeNewsWire
- 4 months ago - Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - GlobeNewsWire
- 5 months ago - Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire